Recent News

• 02.02.2026 - Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
• 01.23.2026 - Nexalin Technology Receives Nasdaq Listing Status Notification
• 01.14.2026 - Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD
• 12.03.2025 - Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
• 12.02.2025 - Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
• 11.18.2025 - Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity
• 11.13.2025 - Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel
• 11.05.2025 - Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
• 10.30.2025 - Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel

Recent Filings

• 01.23.2026 - 8-K Current report
• 01.23.2026 - EX-99.1 EX-99.1
• 12.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.05.2025 - EX-99.1 EX-99.1
• 12.05.2025 - 8-K Current report